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http://dx.doi.org/10.1016/j.ccr.2013.08.020SUMMARYA handful of tumor-derived cell lines form the mainstay of cancer therapeutic development, yielding drugs
with an impact typically measured as months to disease progression. To develop more effective breast
cancer therapeutics andmore readily understand their clinical impact, we constructed a functional metabolic
portrait of 46 independently derived breast cell lines. Our analysis of glutamine uptake and dependence
identified a subset of triple-negative samples that are glutamine auxotrophs. Ambient glutamine indirectly
supports environmental cystine acquisition via the xCT antiporter, which is expressed on one-third of
triple-negative tumors in vivo. xCT inhibition with the clinically approved anti-inflammatory sulfasalazine
decreases tumor growth, revealing a therapeutic target in breast tumors of poorest prognosis and a lead
compound for rapid, effective drug development.INTRODUCTION
Current cancer therapeutic development methodologies are
expensive, slow, and unable to allow early prediction of the pal-
ette and prevalence of responses tumors can mount when chal-
lenged with a prototypic drug. Breast cancer is a challenging
example. Large heterogeneity exists within and between well-
established subtypes and drug responses (reviewed in Weigelt
and Reis-Filho, 2009). Three distinct nomenclatures group
breast tumors based on morphological criteria (e.g., ductal,Significance
There is a strong disconnect between compound efficacy in tu
ical response rates, slowing the production of effective therape
tumor responses to a particular perturbation could be ident
currently used to identify applicable clinical populations, th
sponders. Here, we use functional analyses in 47 independen
related to perturbations in glutaminemetabolism, and estimate
underserved population of patients with breast cancer and a l
450 Cancer Cell 24, 450–465, October 14, 2013 ª2013 Elsevier Inc.lobular, invasive, or in situ); expression of the estrogen receptor
(ER), progesterone receptor (PR), and Her2 receptor tyrosine
kinase (Her2); or molecular phenotype, derived from compre-
hensive mRNA similarities (e.g., luminal, basal). Approximately
one-fourth of breast tumors are ‘‘triple negative’’ (ER/ PR/
Her2; TNBC), and usually have a basal molecular phenotype.
They are aggressive, with poorest prognosis, high mitotic index,
and intrinsic DNA damage repair defects (reviewed in Weigelt
and Reis-Filho, 2009; Alli et al., 2009). A subset termed claudin
low and related metaplastic tumors have rapid disease courses,mor cell lines used for cancer drug development versus clin-
utics. This would be improved if the frequency and types of
ified early in the process. While drug target expression is
ese patient cohorts contain both responders and nonre-
t breast-derived cell lines to measure metabolic responses
their frequency.We identify a therapeutic target in a severely
ead compound for rapid, durable therapeutic development.
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Cancer Cell
Glutamine Sensitivity Analysisstem cell features, and chemotherapy-resistant characteristics
(Hennessy et al., 2009, Prat et al., 2010). No TNBC-targeted ther-
apeutic exists, and patient prognosis is grim.
Many tumors increase uptake and reliance on environmental
nutrients such as glucose, glutamine (reviewed in Souba, 1993;
Gatenby and Gillies, 2004; DeBerardinis et al., 2008), cystine,
and asparagine (Iglehart et al., 1977; Asselin et al., 1989).
Seminal work in tumor series of increasing proliferation rate
and de-differentiation (Erlich ascites, Knox et al., 1970; Morris
hepatoma, Linder-Horowitz et al., 1969; Nb2 lymphoma, Gout
et al., 1997) correlated these features with malignant progres-
sion, fostering drug development efforts focused on specific
nutrients. However, resulting nutrient mimetics were systemi-
cally toxic (reviewed in Souba, 1993), and inexplicable variability
among increasing numbers of tumor isolates eventually
discouraged these endeavors. Only leukemia dependence on
asparagine was successfully pursued to a molecular under-
standing and effective drug (Asparaginase, reviewed in Narta
et al., 2007).
The xCT cystine/glutamate antiporter is the major means of
increasing cystine uptake and the rate-limiting step for gluta-
thione (GSH) synthesis in fibroblasts, rat hepatocytes, and Nb2
lymphoma (Bannai and Tateishi, 1986; Gout et al., 1997). Dual
roles in reactive oxygen species (ROS) neutralization and detox-
ification of xenobiotics such as chemotherapeutics make GSH
an appealing drug target. However, inhibitors of glutathione syn-
thesis failed clinical trials due to toxicities related to systemic
GSH depletion (reviewed in Hamilton and Batist, 2004). xCT
may provide a target for cell-specific GSH depletion. Drug
screens identified off-target effects of the anti-inflammatory
pro drug sulfasalazine (SASP) as an xCT inhibitor (Gout et al.,
2001). SASP, glutamate, monosodium glutamate, and chemical
inhibitors of xCT reduce GSH, increase ROS, potentiate chemo-
therapeutic effects, and attenuate growth in a handful of tumor-
derived cell lines in vitro and xenografts (reviewed in Lo et al.,
2008a). SASP is labile and insoluble under physiological condi-
tions, limiting anti-xCT use to preclinical experiments. Other
effects ascribed to SASP include the on-target anti-inflammatory
activity of an SASP metabolite, NFkB inhibition, and direct inter-
action with GSH in cell-free extracts.
Molecular explanations for glutamine reliance remain elusive,
although the phenomenon is well described (Coles and John-
stone, 1962; Kovacevic and Morris, 1972; Reitzer et al., 1979;
DeBerardinis et al., 2007; Yuneva et al., 2007; Wise et al.,
2008). Glutamine provides carbon and nitrogen for independentFigure 1. Nutrient Consumption in Breast-Derived Cell Lines
(A) Comparison of two nomenclatures used to describe samples in our study. Sa
(B) Fluorescence increase of cell lines after 4 hr culture with 2-NBDG or 6-NBDG
(C) Population doubling times, calculated from standard growth curves.
(D) Glucose uptake at 4 hr (from B) versus glutamine consumption, derived from
(E) Amino acid consumption by four claudin low samples that consume little gl
standard three-letter amino acid codes in key.
(F) Glutamine consumption at 24 hr versus hGAC GeneChip hybridization signal.
three BerEP4+ purified normal breast samples.
(G) Differential hGAC expression by basal versus luminal or ER+ versus ER sam
Chin et al. (2006). The t test p values are below the paired box plots. Error bars e
Icon codes are defined in the figure keys. Dotted lines bracket proliferating, nont
one standard deviation.
See also Figure S1 and Tables S1–S3.
452 Cancer Cell 24, 450–465, October 14, 2013 ª2013 Elsevier Inc.metabolic events, either directly, (e.g., nucleotide and protein
synthesis), via the de-amidated product glutamate (e.g., poly-
saccharide synthesis, membrane antiporter activities), or via
further glutamate deamination to 2-ketoglutarate (2-kg; e.g.,
respiratory/tricarboxylic acid (TCA) cycle substrates; reviewed
in DeBerardinis and Cheng 2010). Abundant serum levels
maintained by skeletal muscle reserves allow most cells to be
glutamine consumers, although they may also be capable of
synthesis (reviewed in Curthoys and Watford, 1995; Kovacevic
and McGivan 1983). Glutaminase (GLS; GLS) and glutamine
synthase (GS;GLUL) modulate intracellular glutamine/glutamate
levels; GLS deamidates glutamine, producing glutamate and
ammonia, while GS synthesizes glutamine from these products.
Reciprocal expression precludes futile substrate cycling (Cur-
thoys and Watford, 1995; Kovacevic and McGivan 1983). GLS
expression levels were correlated with proliferation rate, respira-
tory glutamine use, and environmental glutamine reliance (Knox
et al., 1970; Linder-Horowitz et al., 1969; reviewed in Wise et al.,
2008). Thus GLS is a commonly proposed biomarker of gluta-
mine-dependence and therapeutic target (Lobo et al., 2000;
Lora et al., 2004; Wang et al., 2010, Yuneva et al., 2007; van
den Heuvel et al., 2012), and GLUL a marker of glutamine inde-
pendence (Collins et al., 1998; Kung et al., 2011).
Resurgence of interest in nutrient reliance followed reali-
zations that oncogenes can direct nutrient uptake and de-
pendence (reviewed in Wise and Thompson, 2010). However,
as in other preclinical discoveries, findings in exemplar cell lines
do not identify appropriate patient populations or estimate
their sizes. For example, the metabolic effects of oncogenic
Myc vary substantially between tissue types (Yuneva et al.,
2012), making a simple cause-effect relationship between
oncogenic Myc and glutamine dependence unlikely. Nor does
restricting expectations to tumors of one tissue type improve
the probable efficacy; in singular glioma lines, oncogenic Myc
confers glutamine reliance (Wise et al., 2008), but studies of
multiple glioma lines report little glutamine dependence
(Dranoff et al., 1985). Also, naturally arising tumors without a
dominant oncogenic driver may overcome nutrient scarcity by
switching nutrient sources (Zielke et al., 1978), attenuating
cell cycle progression (Jones et al., 2005), or other activities
reported in nontransformed cells. Finally, nutritional require-
ments of tumors versus proliferating normal cells, rather than
quiescent tissues have seldom been reported (exceptions: Igle-
hart et al., 1977; Jelluma et al., 2006), but are a critical part of
the therapeutic development puzzle. Here we present analysesmple numbers of each type are indicated.
-labeled glucose relative to unlabeled cultures.
media depletion at 24 hr culture, normalized to cell number.
ucose or glutamine compared to HMECd samples. Values derived as in (D);
Green squares on y axis are the average hGAC signals from three CD10+ and
ples in eight clinical breast tumor data sets, downloaded from NCBI GEO and
ncompass highest and lowest values.
umorigenic sample values. Icons represent mean values. Error bars represent
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Figure 2. Glutamine Restriction Slows Culture Expansion
(A) Day 5 culture sizes for each cell line grown in glutamine-free media, normalized to culture in control media.
(B) Day 5 culture sizes in glutamine-free media with twice the normal glucose concentration (23 GU, y axis) versus glutamine-free media with normal glucose
levels (x axis), each normalized to culture in control media.
(C–F) Glutamine deprivation responses in the nontumorigenic exemplar 184A1 and a similarly sensitive tumorigenic line H3153 (arrows in A) are shown.
Growth curves derived from Cell Titer Glow/ATP content analysis (C). Q- #/ATP numbers are the ratio of cell numbers derived from manual counting (trypan
(legend continued on next page)
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Glutamine Sensitivity Analysisof metabolic activities implied by microarray data and identifi-
cation of therapeutic targets enriched in basal and claudin
low TNBC.
RESULTS
Expression profiles of culture-adapted, proliferating nontumori-
genic cells (humanmammary epithelial cell derivatives; HMECd);
freshly purified normal breast epithelia; and purified tumor cells
from patient pleural effusions were derived and merged with
previously published expression profiles of 45 independently
derived breast carcinoma cell lines (see Supplemental Experi-
mental Procedures available online; Neve et al., 2006). These
represent all major breast cancer subtypes and common breast
oncogenes in their natural genetic contexts (Figure 1A; Table
S1). Significance analysis contrasting purified tumors and
tumor-derived cell lines against purified normal breast epithelia
and HMECd lines identified about 760 differentially expressed
probeset IDs (>30%) encoding metabolic proteins (Figure S1A;
Table S2).
Nutrient Preference Varies Widely among Breast
Tumors
Elevated glucose consumption relative to adjacent quiescent
tissue is a canonical hallmark of tumors, but whether this is
due to proliferative glycolytic demands or specific oncogenic
activities is unclear. In analysis of in vitro glucose uptake rates
by tumorigenic versus HMECd lines, we found highest glucose
consumption in luminal carcinoma-derived isolates (Figure 1B).
Claudin low TNBC and approximately one-third of basal samples
consume as little or less glucose than HMECd, although they
preserve many aspects of the aggressive tumors from which
they are derived; (e.g., similar molecular signatures (Neve
et al., 2006), rapid doubling times, (Figure 1C), and extracellular
matrix invasiveness (Sommers et al., 1994, Han et al., 2010).
Thus, glucose consumption varies widely among breast isolates,
and tumorigenic lines do not necessarily consumemore glucose
than nontumorigenic proliferating cells.
Glutamine is an alternate bioenergetic substrate for many
metabolic processes. In amino acid depletion analyses, we
found that most basal and claudin low TNBC consume more
glutamine than the luminal or HMECd samples (Figure 1D). How-
ever, at least four claudin low TNBC consume little glutamine
(black triangles) and do not significantly increase consumption
of another amino acid over that of the HMECd lines, with the
possible exception of cystine (Figure 1E). Thus while nutrient
preference often associates with molecular phenotype, the four
claudin low exceptions reveal this as a generalization. Signifi-
cantly enhanced nutrient consumption may not be an absolute
requisite of aggressive breast tumors.blue)/ATP values. Comparison of AMPK activating phosphorylation, PARP cleav
mitotic figure counts, S-phase fractions, and culture sizes at day 5 culture in indic
differences for high-density versus low-density cultures in glutamine-free media
(G) Glutamine consumption (from Figure 1D) versus glutamine-free culture sizes
(H) hGACGeneChip hybridization signal versus glutamine-free culture sizes from(A
three CD10+ and three BerEP4+ purified normal breast samples.
Dotted lines bracket nontumorigenic sample values; C, complete media; Q, glu
figure keys. Icons represent mean values. Error bars represent one standard dev
454 Cancer Cell 24, 450–465, October 14, 2013 ª2013 Elsevier Inc.Reduced hGAC Expression Identifies Luminal Breast
Carcinomas
We tested historical associations between glutamine consump-
tion and glutaminase expression in our cells. Probeset IDs tar-
geting most portions of GLS (p = 0.6, 0.9, and 0.4), and total
GLS protein levels (Figure S1B, p = 0.19) are not statistically
different between tumor molecular subtypes. However, a GLS
carboxy terminal splice variant (hGAC) is reduced in luminal
carcinomas (Figure 1F; hGAC: 221510_s_at; p = 3.1 3 109;
Elgadi et al., 1999; Figure S1C). hGAC, but not other GLS pro-
beset ID signals, are also lower in ER+ and luminal tumors
compared to ER and basal tumors in eight of eight clinical
breast tumor microarrays examined (Figure 1G; Table S3).
Thus reduced hGAC expression is a strong indicator of luminal
carcinoma identity (t test luminal versus all p = 4.1 3 1013).
While hGAC expression and glutamine consumption modestly
correlate (Figure 1F, p = 0.005), the exceptions in our panel
(black icons between dotted vertical lines) reveal that hGAC
and GLS probeset IDs poorly identify high glutamine
consumers.
Glutamine Restriction Slows Expansion of Most Breast
Cell Lines
Comparison of glutamine restriction responses between
tumorigenic and HMECd samples revealed that 68% of luminal
and 54% of basal TNBC samples were more restriction-resis-
tant than HMECd (Figure 2A). Restriction deficits were not
rescued by increasing the glucose concentration 2- or 5-fold
(Figure 2B, 23 glucose; 53 not shown), suggesting that cells
do not simply switch nutrients like fibroblasts and Erlich asci-
tes (Zielke et al., 1978; Kvamme and Svenneby, 1961) to
exhaust media glucose. Growth curves of HMECd and simi-
larly sensitive tumor lines revealed that glutamine restriction
simply slows culture expansion of each cell type (Figure 2A,
examples at arrows; Figure 2C; Figure S2A). Unlike glucose
restriction, glutamine restriction produces little AMPK activa-
tion (T-172 phosphorylation) indicative of ATP depletion, and
little ACC phosphorylation that would inhibit fatty acid synthe-
sis (Figure 2D). Only a modest increase in cell number/ATP
ratios (Figure 2C, Q #/ATP) and little evidence of apoptosis
by Annexin V staining (data not shown), PARP cleavage (Fig-
ure 2D), or nuclear morphology (Figures S2B–S2E) are seen.
Day 5 cell cycle fractions and mitotic figure counts are also
unchanged (Figure 2E). Culture confluence reduces S-phase
fractions and glutamine sensitivity, indicating that proliferative
drive imparts glutamine reliance (Figure 2E C versus CF,
percent S-phase; Figure 2F). These data predict that normal
proliferating breast progenitors and most breast tumors would
survive a glutamine-restricting therapeutic by simply slowing
expansion rates. Glutamine-free culture sizes do not correlateage, and ACC inhibitory phosphorylation is shown (D). Cell cycle distribution,
ated conditions (E). CF, confluent cells in complete media. Day 5 culture sizes
(F).
from (A).
). Green squares on the y axis are the average hGAC hybridization signals from
tamine-free media; and U, glucose-free media. Icon codes are defined in the
iation. See also Figure S2.
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Figure 3. Glutamine Restriction Induces S-Phase Stalling in a Subset of Basal TNBC
(A) Growth curves of ‘‘glutamine-sensitive’’ carcinomas (underlined in Figure 2A) in glutamine-free media.
(B) Percent increases in annexin V reactivity of cells in glutamine-free media at day 3. Group averages: A, 0.8%, ± 1.4; B, 1.2% ± 1.4; and C, 5.8% ± 3.2; t test A
versus C p = 0.005.
(C) Paired bars representing the change in percent of cells in G2/M (D%G2/M) with nocodazole treatment at day 5 in control (gray) versus glutamine-free (yellow)
media, using cell-cycle-curve-fitting software (FLOJO, Treestar).
(D) Paired bars representing the percent S-phase fraction with nocodazole treatment of day 5 cultures in control (gray) versus glutamine-free (yellow) media.
(legend continued on next page)
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Glutamine Sensitivity Analysiswith glutamine consumption (Figure 2G, p = 0.13) or hGAC
expression (Figure 2H, p = 0.014). We conclude that historical
correlations between these parameters are not applicable to
breast tumors.
Restriction Induces S-Phase Stalling in a Subset of
TNBC
Growth curves of the most restriction-sensitive tumors (Fig-
ure 2A, ‘‘glutamine sensitive’’ underbar) revealed cultures that
(1) continued expansion, similar to HMECd; (2) did not signifi-
cantly expand; and (3) decreased (Figure 3A). Groups B and C
(B+C) include two ER+ (luminal) and 11 TNBC (three basal, eight
claudin low) independently derived samples, including the four
claudin low cells that consume little glutamine (Figures 1D,
black). Group C cells increase Annexin V reactivity (Figure 3B)
and apoptotic figures (Figure S3A) on days 2–4 of restriction.
Thus approximately one-half of our TNBC lines are unable to sur-
vive or expand without glutamine.
We tested whether the few live cells in day 5 group B+C
cultures had arrested in G1, reasoning that they might survive
glutamine restriction to seed tumor recurrences, discouraging
development of glutamine-restricting therapeutics. In complete
media, nocodazole treatment increased G2/M and late S-phase
fractions of all samples tested, demonstrating transit to and acti-
vation of an intact mitotic checkpoint (Figure 3C, gray bars; late
S-phase data not shown; Figure S3B). Glutamine-free cultures of
group A exemplars exhibited similar G2/M increases (gray
versus yellow bars), but not group B or C samples. The un-
changed S-phase fractions rule out G1 arrest by group B+C
samples (Figure 3D, paired gray versus yellow bars). Their cell
cycle profiles are identical with or without nocodazole treatment
(Figure S3C), indicating S-phase stalling, with reduced total and
phosphorylated retinoblastoma proteins similar to S-phase
stalling in DNA damage responses (Figure 3E, Knudsen et al.,
2000). However, like glutamine-restricted Myc-transformed
fibroblasts, gH2A.X phosphorylation is not increased, indicating
that the intra-S-phase DNA damage checkpoint remains inactive
(data not shown; Yuneva et al., 2007). Culture confluence
reduces the S-phase content and glutamine sensitivity of all
but two group C samples (Figure 3F, colored versus gray
icons). However, group B+C samples are not simply the most
rapidly dividing cells (Figure 3G; t tests: all versus C+B, p =
0.11; all basal and claudin low versus C+B, p = 0.2), indicating
that they harbor specific defects that make them unable to
surmount restriction.
Known Regulators of Glutamine Metabolism Do Not
Identify Group B or C Cells
We tested proposals that hGAC and GLUL identified glutamine-
dependent cells. While hGAC statistically identifies group C (p =
5.6 3 109) and group B+C (p = 0.008) cells, only 9/13 (69%)
samples expressing higher hGAC than HMECd cells are group(E) S-phase stalling is accompanied by a decrease in total and serine 780 phosp
(F) Culture confluence reduces S-phase fractions and glutamine sensitivity; S-pha
(gray icons) versus low density culture (colored icons); paired icons connected b
(G) Doubling time (from Figure 1C) versus glutamine-free culture sizes (from Figu
Icon codes are defined in the figure keys. Icons represent mean values. Error ba
See also Figure S3.
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are similar to purified normal epithelia (green squares). hGAC
also poorly discerns group C (p = 0.03) or B+C (p = 0.17) from
all other TNBC. While GLUL levels correlate with restricted cul-
ture sizes (Figure 4B; p = 0.005–2.334, three probeset IDs; Fig-
ure S4A),GLUL also more accurately discerns luminal from clau-
din low samples (Figure 4B; p = 1.9 3 105). At lower p values,
GLUL discerns luminal from all basal + claudin low (p = 2.5 3
105 to 1.9 3 104), or ER+ from ER (p = 4.4 3 103 to 1.2 3
102) cell lines, and samples in seven of eight clinical expression
data sets (Figure 4C; Table S4). Most group B+C cells express
less GLUL than normal samples (Figure 4D), but low expression
is not unique to group B+C (gray circles below lower dotted line).
Nor can GLUL discern group C (p = 0.20–0.67) or B+C samples
(p = 0.015–0.09) from other TNBC. Thus, hGAC and GLUL are
not strong biomarkers for group B or C type tumors.
OncogenicMyccandrive glutamineuptake anddependence in
exemplar fibroblasts and glioma (Wise et al., 2008; Gao et al.,
2009; Yuneva et al., 2007). CMYC is enriched in our basal and
claudin low cells (p = 0.013). But neither CMYC, other Myc family
members, or core MYC expression signature genes (Chandriani
et al., 2009) are differentially expressed in group C or group
B+Ccells versusotherbasal +claudin lowcells (FigureS4B;Table
S5).Wealso foundnocorrelationbetweenTP53mutational status
andgroupBorCmembershipusing the IARCTP53database (see
Supplemental Experimental Procedures, p = 0.7; http://p53.iarc.
fr/CellLines.aspx). Significanceanalysis contrastinggeneexpres-
sion in thegroupCorB+Csamplesversusotherbasal andclaudin
low TNBC did not identify potential biomarkers or offer molecular
explanations for S-phase stalling (data not shown).
Group B and C Carcinomas Are Glutamine Auxotrophs
Glutamine restriction reduces hGAC and GLUL mRNA levels in
low-density cultures, while producing little change in GS protein
levels (Figures 4E, 4F, S4C, and S4D). Confluent cultures can
induce GLUL mRNA (Figure 4E, e.g., M435), suggesting one
mechanism for their starvation resistance. But we conclude
that proliferating breast tumors cannot induce GLUL to escape
glutamine restriction.
Titrations of 17 common carbon sources over four concentra-
tion logs were tested for rescue of an exemplar group C carci-
noma (M436) from glutamine restriction (Figure S4E). Neither
these nor nitrogen sources, ammoniumchloride, choline chloride,
or putrescine, improved cultures (Figure S4F). Only glutamate (2-
to 3-fold), oxaloacetate (2%–6%), and dimethyl 2-ketoglutarate
(2%–10%; Figure S4G) increased ATP values slightly; however,
only glutamate increased viable cell numbers in multiple group
C cell lines (4%–6%; Figure S4H). Combining GS substrates,
glutamate and nitrogen sources, did not further improve cultures
(FigureS4I).Weconclude it unlikely that other commonlyavailable
nutrients can substitute for glutamine during restriction, and that
the group C+B tumors are functional glutamine auxotrophs.horylated retinoblastoma protein.
se decrease (D%) is the decrease in percent S-phase with high density culture
y dashed lines represent a single cell line.
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rs represent one standard deviation.
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Figure 4. Common Regulators of Glutamine Metabolism Do Not Identify Auxotrophic Cells
(A) hGAC GeneChip hybridization signal (log2) versus glutamine-free culture sizes (from Figure 2H) coded as restriction groups B and C versus others.
(B) GLUL GeneChip hybridization signal (log2) versus day 5 glutamine-free culture sizes, coded by molecular subtype.
(C) GLUL expression by basal versus luminal or ER+ versus ER samples in eight clinical breast tumor expression data sets, downloaded from NCBI GEO and
Chin 2006 (Chin et al., 2006); t test p values are below paired boxplots. Error bars encompass highest and lowest values.
(D) Correlation of glutamine-free culture sizes and GLUL expression as in (B), but coded by restriction groups.
(E and F) Comparison of (E)GLUL and (F) hGACmRNA levels at day 3 in glutamine replete versus deficient media, from quantitative PCR analysis. L, low density;
C, confluent; and Q, glutamine.
Icon codes are defined in the figure keys. Green squares, average hybridization signals from three CD10+ and three BerEP4+ purified normal breast samples.
Icons represent mean values. Error bars represent one standard deviation. Dotted lines bracket proliferating, nontumorigenic sample values.
See also Figure S4 and Tables S4 and S5.
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Figure 5. Glutamine Auxotrophy Presents Therapeutic Opportunities
(A) GeneChip hybridization signals for four glutamine transporters and the common heavy chain (SLC3A2) in glutamine auxotrophic cells. Error bars encompass
highest and lowest values.
(B) GeneChip hybridization signals for transporters as in (A), for basal carcinoma subsets of clinical data sets downloaded from NCBI GEO and Chin 2006 (Chin
et al., 2006), one example data set shown. Error bars encompass highest and lowest values.
(C) Relative asparaginase (y axis), and DON (x axis) sensitivities (IC85) of our cell panel, coded by restriction groups B and C versus others. Dotted line, as-
paraginase concentration used to kill sensitive leukemia cells in vitro (1 u/ml).
(D) Day 5 glutamine-free culture sizes (from Figure 2A) versus asparaginase sensitivity (IC50 shown).
(E) Four-fold drug titrations and calculated IC50s for an exemplar group C auxotroph (M436). D0, highest drug concentration and calculated IC50s in figure key;
Asp, asparaginase; Pac, paclitaxel; and Dox, doxorubicin.
(legend continued on next page)
Cancer Cell
Glutamine Sensitivity Analysis
458 Cancer Cell 24, 450–465, October 14, 2013 ª2013 Elsevier Inc.
Cancer Cell
Glutamine Sensitivity AnalysisGlutamine Auxotrophy Presents Therapeutic
Opportunities
We tested three approaches to therapeutic development target-
ing auxotrophic TNBC: preventing glutamine access, inhibiting
glutamine-dependent enzymes, and inhibiting activities
requiring glutamine metabolites. Auxotrophs (Figure 5A) and
basal carcinoma subsets in clinical microarray data sets
(Figure 5B, example; Table S6) express multiple glutamine trans-
porters. Thus we prevented glutamine access by treating
cultures with the leukemia therapeutic asparaginase, reducing
asparagine and glutamine to their acidic derivatives (Figure S5A;
Narta et al., 2007). This produced an apparent synthetic lethality
at concentrations equal to that of leukemia in all group C and in
approximately one-third of group B cells (Figure 5C, 85% inhib-
itory concentration [IC85] below dotted line; Asselin et al., 1989).
Correlated asparaginase sensitivities and glutamine-free culture
sizes (Figure 5D, p = 5.7 3 106; asparaginase IC84; p = 9.3 3
109, not shown) reveal that glutamine re-synthesis from the as-
paraginase products glutamate and ammonia is uncommon. We
propose that local asparaginase/glutaminase delivery would kill
auxotrophic tumors without requiring selective identification and
targeting of their potentially varied molecular defects. Cells
relatively resistant to paclitaxel or doxorubicin are exquisitely
asparaginase-sensitive, indicating that an asparaginase-like
therapeutic could become a critical, independent alternative
for drug-resistant tumors (Figure 5E).
Analysis of 13C-5-glutamine-derived metabolites in the group
C TNBC M436 (Figure 5F; Table S7) revealed that 80% of intra-
cellular glutamine is imported (all five carbon positions are 13C-
labeled). Approximately 40% of TCA cycle metabolites and their
derivatives are directly produced from this pool, and another
one-third (27%–30%) are partially 13C-labeled. Glutamine re-
striction depletes these pools (Figure 5G), suggesting that inhibi-
tion of glutaminase (GLS/hGAC) or aminotrasferases (ATs) might
kill or slow growth of the auxotrophs. siRNA-mediated reduction
of hGAC-attenuated culture expansion of auxotrophs with high
glutamine consumption rates (Figure 5H, M436, M231; Fig-
ure S5B), but provided little efficacy against BT549, an auxo-
troph that consumes little glutamine (Figure 1D), or H1937, a
group A TNBC. In comprehensive tests, treatment with a broad
spectrum inhibitor of amidotransferases including GLS
(6-diazo-5-oxo-L-norleucine; DON; reviewed in Souba, 1993)
placed auxotrophs among the most sensitive samples (Fig-
ure 5C). We propose that inhibitors of single DON targets should
be refined for use against auxotrophic TNBC.
Glutamine Is Required for ROS Control in TNBC
Finally, we tested the strategy of inhibiting an activity that re-
quires glutamine metabolites. In the normal human fibroblast
IMR-90, one-third of glutamine uptake supplies glutamate for
xCT exchange activity (Bannai and Ishii, 1988). Analysis of amino
acid consumption revealed highly correlated cystine depletion(F) TCA cycle diagram illustrating respiratory use of glutamine in red arrows.
metabolite that contains (all/several/no) 13C-carbons derived from culture with 13
(G) Decrease in key TCA cycle metabolite pools with glutamine restriction, expre
(H) Proliferative effects of siRNA-mediated hGAC mRNA reduction in exemplar c
Icon codes are defined in the figure keys. Icons represent mean values. Error ba
See also Figure S5 and Tables S6 and S7.
Cand glutamate secretion in 27 of our lines (Figure 6A, p = 8.8 3
1011; Figure S6A), suggesting xCT activity. Glutamine restric-
tion strongly reduced exchange (Figure 6B), modestly decreased
GSH levels (Figure 6C) and increased intracellular ROS by at
least 30% in 8/19 TNBC (Figure 6D, light blue). This is partially
corrected by the ROS scavenger N-acetylcysteine (NAC) in 12/
13 samples (light gray). NAC does not allow culture expansion
(Figure S6B), thus, glutamine use for ROS control is common,
but other glutamine-influenced factors are also required for
auxotroph proliferation.
Wedirectly assessed the xCTexpression and function in TNBC
that was implied by the glutamine restriction effects on ROS.
Basal and claudin low lines overexpress the xCT exchange-spe-
cific subunit SLC7A11 (Figure 6E, p = 0.06–7.4 3 104; Fig-
ure S6C), the glutamate-cysteine ligase regulatory subunit of
glutathione synthase (arrow;GCLM, p = 0.011), and amembrane
interacting protein CD44 p = 0.005–5.9 3 108; Ishimoto et al.,
2011). Cystine consumption and SLC7A11 mRNA levels corre-
late (Figures 6F and S6D), and siRNA-mediated reduction of
SLC7A11 mRNA increases intracellular ROS (Figures 6G and
6H). SASP treatment reduces cystine/glutamate exchange and
GSH content (Figures 6B and 6C). 2-mercaptoethanol (2me) pro-
vides cystine asmixed 2me-cysteine disulfides (Ishii et al., 1981),
and normalizes GSH levels, demonstrating SASP specificity for
cystine and GSH production. In 18/19 TNBC, SASP increases
endogenous ROS by at least 50% (Figure 6D, teal bars), which
are reduced by NAC in 14/16 samples (dark gray bars). Using
reagents for specificROSspecies,we found that SASP increases
hydroxyl radicals, in keeping with the expected effects of GSH
depletion (Figure S6E; Franco et al., 2007). Thus, the xCT anti-
porter is commonly expressed and functional in TNBC. HMECd
expresses these genes (Figure 6E, columns ‘‘I’’), but xCT is
much less active (Figure 6A, green).
SASP Treatment Attenuates Tumor Growth
In proliferation assays, we found that SASP treatment dramati-
cally reduces TNBC culture sizes with half-maximal inhibitory
concentration (IC50) values modestly correlated to cystine up-
take in complete media (Figure 7A, p = 0.07). Culture sizes are
significantly restored by NAC (Figure 7B) and not affected by
the active anti-inflammatory fragment of SASP, 5-aminosalicylic
acid (5-ASA; Figure S7A). Thus inhibition of cystine acquisition,
not anti-inflammatory activity, is responsible for TNBC prolifera-
tive sensitivity. This concentration range (0.2–0.7 mM) is not far
from serum concentrations measured in bowel inflammatory
patients (0.18 mM; Guastavino et al., 1988). Under normoxic
conditions (5% O2), SASP sensitivity increased 2- to 3-fold (Fig-
ure S7B), and SASP significantly slowed growth of an auxotro-
phic line xenograft (Figure 7C), indicating that xCT activity is
also critical for growth in vivo. Accordingly, 8/20 anonymous
TNBC clinical specimens strongly express xCT (Figure 7D
and S7C–S7K). TNBC can be treated with carboplatin, andNumbers indicate mass spectroscopy determination of the percent of each
C-5-glutamine in M436.
ssed as percent control media cultures. Q, glutamine-free media.
ell lines, expressed as a percent of transfection with a scrambled siRNA.
rs represent one standard deviation.
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Figure 6. Glutamine Restriction and xCT Inhibition Increase ROS
(A) Change in media cystine (x axis) and glutamate (y axis) concentrations of cells cultured 24 hr in control media.
(B) Twenty-four hr of glutamine restriction or SASP treatment reduces cystine/glutamate exchange by exemplar group C auxotrophs. cys, cystine and glu,
glutamate.
(C) Effects of 24-hr glutamine restriction or SASP treatment on GSH content in an exemplar group C TNBC; Q, glutamine-free media; SASP, SASP treatment in
complete media; and SASP + 2me, SASP treatment in the presence of beta-mercaptoethanol.
(D) ROS levels in basal carcinomas assessed with DCFHDA fluorescence, normalized to control media reactivity. Light blue, 2-day cultures in glutamine-
free media. Group averages: A, 112% ± 21; B, 121% ± 31; C, 162% ± 59; t test group A versus C, p = 0.07; and group A versus B+C, p = 0.074. Light gray,
(legend continued on next page)
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Glutamine Sensitivity Analysiscarboplatin + SASP reduces the carboplatin IC50 in 13/14 of our
TNBC samples (Figure 7E).We propose that SASP be derived for
clinical use.
DISCUSSION
Rodent breast tumors (Erlich Ascites series) were instrumental in
the definition of central metabolic pathways and tumor-specific
aberrations, but work in human breast tumors is largely limited
to aspects of fatty acid metabolism (see Menendez and Lupu,
2007). Reports of other metabolic features are less frequent
and use only one or a few samples, producing biased conclu-
sions due, for example, to the mistaken use claudin low lines
to represent typical TNBC; misidentification of GeneChip probe-
set IDs that are hGAC splice variant specific as reporting total
GLS mRNA; the lack of gene expression comparisons between
tumors and normal breast epithelia; and the inability to directly
compare nontumorigenic breast derivative and tumorigenic
behaviors (for examples, see Collins et al., 1998; Kung et al.,
2011; Simpson et al., 2012). Our data clarify these misunder-
standings and provide a detailed nutrient utilization portrait of
a comprehensive organ site-specific tumor collection, contrast-
ing gene expression and functional assays to define common
nutrient utilization patterns and responses to drugs that leverage
associated metabolic activities.
Historically Associated Metabolic Features Vary
Substantially in Breast Cancer
Doubling time, glutamine consumption, and glutamine reliance
are historically correlated. Among this triad, only doubling time
and glutamine-free culture sizes modestly correlate across our
large sample collection (Figure 3G, p = 0.002). However, the
glutamine auxotrophs are not simply the most rapidly dividing
samples. Nor are they the largest glutamine consumers; four of
eight auxotrophic, claudin low samples consume no more gluta-
mine than proliferating nontumorigenic cells (Figure 1D, black tri-
angles: BT549, H38, H100, M157). Glutamine can be cycled by
import via ASCT2 and export in exchange for essential amino
acids via the LAT1/4f2hc antiporter (SLC7A5/SLC3A2, Figure 7F,
dark blue arrows; Nicklin et al., 2009). Our four low glutamine
consumers express all antiporter components (Figure 5A), and
glutamate cycling would not deplete measured ambient gluta-
mine levels. Thus, these cells may require glutamine to fuel
both this exchange activity and the xCT antiporter and use rela-
tively less glutamine for respiration. This may explain the relative
proliferative resistance to siRNA-mediated reduction of hGAC
seen in BT549 (Figure 5H). Differences between glutamine
cycling and catabolismmay also partially explain historically var-
iable correlations between glutamine uptake and glutamine reli-
ance in other tumors.glutamine-free media +NAC. Teal, cultures treated 24 hr with SASP. Group avera
0.019; and group A versus B+C, p = 0.003. Dark gray, SASP +NAC.
(E) Heatmap of genes involved in xCT function: red, increased and green, decreas
nontumorigenic cell lines; and PE, ER+ tumor cells purified from pleural effusions
(F) SLC7A11 GeneChip hybridization signal (log2) versus cystine consumption, ic
(G) ROS levels in M231, 48 hr after targeting SLC7A11 or a scrambled siRNA, in
(H) SLC7A11 knockdown efficiency of siRNAs used in (G).
Icon codes are defined in the figure keys. NAC, N-acetylcystine and SASP, su
deviation. Amino acid quantitation obtained with HPLC. See also Figure S6.
CConversely, auxotrophs of high glutamine consumption (Fig-
ure 1D; M436) that require glutamine as a major respiratory
fuel (Figures 5F and 5G; Figure 7F, light blue arrows) and for
glutamate/cystine exchange (Figures 6B and 7F, gray arrows),
may be more susceptible to inhibition of hGAC (Figure 5H;
M436, M231) and subordinate glutamate-dependent activities
such as aminotransferases (ATs; Thornburg et al., 2008). Thus
within a single tumor cell line, multiple critical requirements for
glutamine may exist and provide multiple therapeutic targets,
either individually or in combination. We hypothesize that xCT
inhibition may be further potentiated by limiting glutamate avail-
ability (Figure 7F).
Historically Proposed Genetic Indicators of Glutamine
Reliance Do Not Define Auxotrophy
With the resurgent interest in tumor metabolism, metabolic
genes such as GLS and GLUL have been re-asserted as poten-
tial therapeutic targets and biomarkers, but we find that thera-
peutic relevance is not so easily defined. Gene expression may
suggest metabolic behaviors that are more likely active in
specific tumor groups, such as a statistical association of
hGAC with high glutamine consumption in basal and claudin
low versus luminal tumors (Figures 1F). However, neither hGAC
nor GLUL defines high glutamine consumption or identifies the
true auxotrophic group B and/or C cells with appropriate sensi-
tivity to be considered independent clinical biomarkers. We also
find that responses to interruption of ongoingmetabolic activities
can vary substantially due to unknown cell-intrinsic factors. For
example, individual tumors can respond to glutamine restriction
by slowing culture expansion or stalling in S-phase and dying
(Figures 3A–3C). Molecular explanation(s) for S-phase stalling
remain unclear and may be due to tumor defects far removed
from direct glutamine interaction.
xCT Is a Compelling Therapeutic Target for
Triple-Negative Tumors
Inhibitor and RNAi studies reveal xCT induction as the dominant
means of increasing cystine acquisition to accelerate GSH syn-
thesis (reviewed in Lo et al., 2008a). Thus xCTmay be a target for
cell-specific GSH depletion, because SASP and other xCT inhib-
itors can slow growth of exemplar cell lines in xenograft without
significant effects on other organs and can cooperate with che-
motherapeutics such as cisplatin (Okuno et al., 2003), geldana-
mycin (Huang et al., 2005), doxorubicin (Narang et al., 2007),
and gemcitabine (Lo et al., 2008b). Currently, the SASP structure
is labile, designed to be cleaved by enteric bacteria to release an
active anti-inflammatory fragment. It is also insoluble in aqueous
solutions and not optimized for the fortuitous interaction with
xCT. Thus while direct clinical applications to TNBC are unreal-
istic, SASP is a strong lead compound for development of xCTges; A, 205% ± 43; B, 287% ± 62; C, 405% ± 168; t test group A versus C, p =
ed; N, purified normal CD10+ and BerEp4+ breast epithelial cells; I, proliferating
.
ons coded by molecular subtype.
the presence or absence of N-acetylcystine (NAC).
lfasalazine. Icons represent mean values. Error bars represent one standard
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Figure 7. SASP Attenuates Proliferation In Vitro and In Vivo
(A) Cystine consumption in complete media derived from HPLC analysis (x axis) versus SASP sensitivity (IC50).
(B) NAC treatment rescues SASP-induced culture size defects in an exemplar cell from each restriction group A–C.
(C) SASP treatment attenuates xenograft growth; group average tumor volumes separation p values noted on graph.
(D) Examples of xCT expression in exemplar human TNBC tumor sections. Nuclei, blue and xCT-specific HRP signal, brown; upper positive, lower negative.
(E) SASP reduces the carboplatin IC50 of most basal TNBC; paired icons connected by dashed lines represent a single TNBC. Colored icons, carboplatin IC50;
gray icons, IC50 of carboplatin plus 300 mM SASP; and Q insens., basal TNBC with less glutamine-sensitivity than non-tumorigenic cells.
(F) Summary of discussed glutamine catabolic activities. Red, compounds tested in this manuscript; green, activities with potential therapeutic
inhibitory importance in glutamine-avid TNBC; dark blue, LAT1 glutamine/leucine antiporter and ASCT2, system ASC glutamine transporter; gray, xCT, the
(legend continued on next page)
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Glutamine Sensitivity Analysisinhibitory therapeutics. Our studies reveal that SLC7A11 expres-
sion, cystine/glutamate exchange activity (Figures 6A, 6E, and
7D), and deleterious proliferative effects of xCT inhibition are
common in basal and claudin low carcinomas (Figures 7A and
7C). CD44 and the claudin low gene expression signature asso-
ciate with breast cancer stem-cell phenotypes (Hennessy et al.,
2009, Prat et al., 2010), implying that SASP-derived therapeutics
may target breast tumor stem cells. This is reminiscent of CD44
and xCT-dependent ROS regulation in gastric tumor progenitors
(Ishimoto et al., 2011). Thus we have identified a compelling ther-
apeutic target commonly expressed by breast tumors of poorest
prognosis, and a lead compound for rapid, effective drug
development.
EXPERIMENTAL PROCEDURES
Data Set Preparation
See Supplemental Experimental Procedures.
Cell Culture
Tumorigenic cell lines were adapted to RPMI or DMEM + 5% FBS (GIBCO
11875 and 11965; Table S2). Culture expansion assays performed at least
three times in triplicate, in 96-well format. Relative cell number was determined
(Cell Titer Glow, Promega) and verified with microscopy. Averages
reported ±SD (see Supplemental Experimental Procedures and below).
siRNA Effects
Transfections (Oligofectamine, Life Technologies 12252-011) used SLC7A11
(SilencerSelect Validated s24291, Life Technologies), hGAC (Dharmacon
custom synthesis, sense: GGAAAGUCUGGGAGAGAAAUU, antisense: UUU
CUCUCCCAGACUUUCCUU), or nonspecific siRNAs (sc-37007, Santa Cruz
Biotechnology; SN-1002, Bioneer), in triplicate sub-confluent six-well or 96-
well plates and the Life Technology protocol. RNA and ROS quantitation
were performed at day 2.
Glucose Uptake
Cultures in Dulbecco’s modified Eagle’s medium/low glucose (GIBCO 11885),
RPMI, or HMEC (Medium 171, Cascade Biologics), were treated with or
without 2-NBDG or 6-NBDG glucose (30 mM, Molecular Probes N13195,
N23106) for 0–8 hr, harvested, external fluorescence quenched (0.4% trypan
blue), and 30,000 cells analyzed in triplicate FACSCalibur (Becton Dickinson)
or C6 Flow Cytometer (Accuri). Average mean fluorescence values at 4 hr
normalized to unstained controls are reported as ± SD.
ROS Detection
Cells were incubated for 15 min with 10 mM 20,70-dichlorofluorescein diacetate
(DCFH-DA, Sigma D6883), or 1 hr with 5 mM 30-(p-hydroxyphenyl) fluorescein
(HPF, Molecular Probes H36004), harvested, and 30,000 cells analyzed in trip-
licate by FACS, normalized to unstained controls. Average mean fluorescence
values are reported as ± SD.
GSH Quantitation
We used the ApoGSH Glutathione Detection Kit (BioVision) per manufacturer’s
instructions in triplicatewith2-meat60mM.Averagevaluesare reportedas±SD.
Amino Acid Analysis
Supernatants from 24-hr subconfluent duplicate or triplicate cultures and
cell-free media were analyzed using standard high-performance liquid chro-
matography (HPLC) techniques (Biochemical Genetics Laboratory, Stanford
University; UC Davis Genome Center, UC Davis). Values were subtractedglutamate/cystine antiporter; light blue, glutamine anaplerosis path; SASP, sulfa
aminotransferases; GS, glutamine synthase; GLS, glutaminase; and hGAC, carbo
or DON targets are illustrated.
Icon codes are defined in the figure keys. Icons represent mean values. Error ba
Cfrom media controls, normalized to cell number. Average values are reported
as ± SD.
Metabolite Analysis
Cells were cultured in the presence of 13C-5 labeled glutamine (Cambridge
Isotope) for 0–12 hr, PBSwashed, frozen (dry ice), lyophilized, pellets weighed,
and homogenized in cold 60% acetonitrile (40 ml per 1 mg of protein with
acetonitrile-washed glass beads). Samples were incubated for 30 min at
80C, supernatants collected, and pellets washed (60% acetonitrile). Pooled
supernatants were lyophilized, resuspended in 200 ml H20, and 40 ml mixed
with 30 ml of 40% TCA and 50 ml of 0.1 mM noreleucine (Sigma; internal stan-
dard). Lyophilized samples were silylated (50 ml acetonitrile: MTBSTFA;
N-methyl-N-tert-butyl-dimethylsilyltrifluoroacetamide, Regis Chemical, Mor-
ton Grove, IL, v/v 1:1), sonicated for 3 hr, and incubated overnight. Analysis
used a PolarisQ GC-ion trap mass spectrometer (ThermoFinnigan, Austin,
TX) as previously described (Yuneva et al., 2012). Metabolites were identified
and quantitated using XCalibur software (ThermoFinnigan). Results were
normalized to dry pellet weight, and noreleucine standard. Average values
are reported as ± SD.
Immunohistochemistry
Cell lines and anonymous, de-identified tumor sections (UCSF/SPORE Tissue
Core, collected under UCSF Internal ReviewBoard approval) with high and low
SLC7A11 values (Chin et al., 2006), were stained to correlate anti-xCT reac-
tivity (Novus Biologicals NB300-318) with SLC7A11 mRNA levels (data not
shown). Detection used citrate antigen retrieval, ABC Kit (Vector Labs), and
the Novus antibody-specific protocol. Commercial tissue arrays of anony-
mous breast tumor and normal sections with known ER/PR/Her2 status
were purchased and analyzed (Biomax).
Bioinformatics
Association of GLS and GLUL expression with ER status and molecular sub-
type was determined in clinical microarrays available at http://www.ncbi.
nlm.nih.gov/gds. Data were preprocessed (RMA algorithm in R), and analyzed
with Matlab R2011a and R version 2.12.0 for MacOS X. Pearson correlations
are reported; class distinctions by Student’s t test.
Xenografts
The claudin low auxotroph M231 was implanted into mammary fatpad 4 in
fourteen 6-week-old NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) female mice.
Animals were randomized at day 16 and injected intraperitoneally twice daily
with 250 ml saline or 50 mM SASP in 0.1 N NaOH pH 7.5 from days 17 to 31
(Guan et al., 2009). Tumor volume was measured twice weekly,and average
values reported as ±SD. Experiments performed following UCSF Institutional
Animal Care and Use Committee approval, in accordance with institutional
and national guidelines.
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